Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L04 IMMUNOSUPPRESSANTS
L04A IMMUNOSUPPRESSANTS
L04AF Janus-associated kinase (JAK) inhibitors
L04AF08 Ritlecitinib
D11970 Ritlecitinib tosylate (USAN) <JP/US>
USP drug classification [BR:br08302]
Immunological Agents
Immunological Agents, Other
JAK Inhibitors
Ritlecitinib
D11970 Ritlecitinib tosylate (USAN)
Therapeutic category of drugs in Japan [BR:br08301]
3 Agents affecting metabolism
39 Other agents affecting metabolism
399 Miscellaneous
3999 Others
D11970 Ritlecitinib tosylate (USAN); Ritlecitinib tosilate (JAN)
Drug groups [BR:br08330]
Anti-inflammatory
DG01985 Disease modifying anti-rheumatic drug (DMARD)
DG02020 JAK inhibitor
D11970 Ritlecitinib tosylate
Metabolizing enzyme inhibitor
DG01634 CYP1A2 inhibitor
D11970 Ritlecitinib tosylate
DG02852 CYP3A/CYP3A4 inhibitor
D11970 Ritlecitinib tosylate
Target-based classification of drugs [BR:br08310]
Protein kinases
Non-receptor tyrosine kinases
JAK family
JAK3
D11970 Ritlecitinib tosylate (USAN) <JP/US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D11970
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D11970
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D11970
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D11970
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D11970